<div><div></div><div><span><p><strong><span>Outlook Therapeutics completed a registered direct offering of 8,539,709 common shares to GMS Ventures and Investments.</span></strong></p><p><strong><span>Key Highlights:</span></strong></p><ul><li><span>Company sold 8,539,709 shares of common stock to GMS Ventures and Investments under a securities purchase agreement dated May 28, 2026.</span></li><li><span>Offering was executed as a registered direct offering using the company’s effective Form S-3 registration statement (File No. 333-278340).</span></li><li><span>The Form S-3 originally filed March 28, 2024 became effective April 5, 2024, and the sale was made pursuant to its base prospectus and prospectus supplement.</span></li></ul><p><span>Original SEC Filing: </span>Outlook Therapeutics, Inc. [ OTLK ] - 8-K - May. 29, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

OTLK

<p>Outlook Therapeutics completed a registered direct offering, selling approximately 8.54 million common shares to GMS Ventures and Investments. The transaction was executed under a securities purchase agreement dated May 28, 2026, utilizing the company's effective Form S-3 registration statement. This event is classified as corporate finance related information.</p>

TradingView

Outlook Therapeutics

iShares Biotechnology ETF

VG Health

SPDR S&P Biotech

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

Proshares UltraShort Nasdaq Biotech

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bear 3X

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Outlook Therapeutics sells 8.54M shares in registered direct offering to GMS Ventures